Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | GPR183 | P32249 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | F2R | P25116 | 1/20 | 0.48 |
| ▸ | AR | P10275 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4375996 | 1.00 | APP (0.55) | APPKMT2AGPR183MAPTL3MBTL1 | |
| SCHEMBL13635997 | 0.87 | KMT2A (0.55) | APPKMT2AGPR183MAPTL3MBTL1 | |
| SCHEMBL4379006 | 0.87 | KMT2A (0.55) | APPKMT2AGPR183MAPTL3MBTL1 | |
| SCHEMBL13636352 | 0.86 | MAPT (0.69) | APPKMT2AGPR183MAPTL3MBTL1 | |
| SCHEMBL4379116 | 0.86 | MAPT (0.69) | APPKMT2AGPR183MAPTL3MBTL1 | |
| SCHEMBL4375435 | 0.84 | KDM4E (0.64) | APPKMT2AGPR183MAPTL3MBTL1 | |
| SCHEMBL13636493 | 0.84 | KDM4E (0.64) | APPKMT2AGPR183MAPTL3MBTL1 | |
| SCHEMBL13636224 | 0.82 | KMT2A (0.83) | KMT2AMAPTL3MBTL1POLBMEN1 | |
| SCHEMBL4384009 | 0.82 | KMT2A (0.83) | KMT2AMAPTL3MBTL1POLBMEN1 | |
| SCHEMBL791546 | 0.80 | HPGD (0.65) | APPKMT2AGPR183MAPTL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1421071-B1 | SUBSTITUTED PIPERAZINE AND DIAZEPANE DERIVAIVES AS HISTAMINE H3 RECEPTOR MODULATORS | HIGH POINT PHARMACEUTICALS LLC (US) | 2009-11-18 | — | — | EP | disclosed |
| US-20080113968-A1 | Substituted piperazines and diazepanes | NOVO NORDISK A/S (DK) | 2008-05-15 | — | — | US | disclosed |
| US-20080113968-A1 | Substituted piperazines and diazepanes | NOVO NORDISK A/S (DK) | 2008-05-15 | — | — | US | disclosed |
| US-7208497-B2 | Substituted piperazines and diazepanes | NOVO NORDISK A/S (DK) | 2007-04-24 | — | — | US | disclosed |
| US-7208497-B2 | Substituted piperazines and diazepanes | NOVO NORDISK A/S (DK) | 2007-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113968-A1 | Substituted piperazines and diazepanes | HRH3, HRH4, HRH1 | APP 892/4885KMT2A 295/4885GPR183 264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.